Responses of HDL subclasses, Lp(A-I) and Lp(A-I:A-II) levels and lipolytic enzyme activities to continuous oral estrogen-progestin and transdermal estrogen with cyclic progestin regimens in postmenopausal women

Atherosclerosis

Volumn 129, Issue 2, 1997, Pages 249-259

  Tilly Kiesi, Marju ^a   Kahri, Juhani ^a   Pyörälä, Tapani ^b   Puolakka, Jukka ^b   Luotola, Hannu ^b   Lappi, Mikko ^a   Lahdenperä, Sanni ^a   Taskinen, Marja Riitta ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b JYVÄSKYLÄ CENTRAL HOSPITAL   (Finland)

Author keywords

HDL subclasses; lipoprotein(A I); lipoprotein(A I:A II); medroxyprogesterone acetate; norethisterone acetate; transdermal 17 estrogen

Indexed keywords

CHOLESTEROL; ESTRADIOL; ESTRADIOL PLUS NORETHISTERONE ACETATE; HIGH DENSITY LIPOPROTEIN; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE ACETATE; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; FEMALE; GEL ELECTROPHORESIS; HUMAN; LIPID METABOLISM; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PRIORITY JOURNAL; TRANSDERMAL DRUG ADMINISTRATION;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; APOLIPOPROTEIN A-I; APOLIPOPROTEIN A-II; CARRIER PROTEINS; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; GLYCOPROTEINS; HEPARIN; HUMANS; LIPOLYSIS; LIPOPROTEIN(A); LIPOPROTEINS, HDL; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; NORETHINDRONE; POSTMENOPAUSE; PROGESTERONE CONGENERS; TRIGLYCERIDES;

EID: 0030898016     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(96)06036-4     Document Type: Article

References (66)

1. Stampfer MJ, Willett WC, Coldiz GA, Rosner B, Speizer FE, Hennekens CH. A prospective study of postmenopausal estrogen therapy and coronary heart disease. N Engl J Med 1985;313:1044.
2. Bush TL, Barrett-Connor E, Cowan LD, Criqui MH, Wallace, RB, Suchindran CM, Tyroler HA, Rifkind BM. Cardiovascular mortality and noncontraceptive use of estrogen in women: Results from Lipid Research Clinics Program Follow up Study. Circulation 1987;75:1102.
3. Barrett-Connor E, Bush T. Estrogen and coronary heart disease in women. JAMA 1991;14:1861-1867.
4. Manolio TA, Furberg CD, Shemanski L, Psaty BM, O'Leary DH, Tracy RP, Bush TL. Associations of postmenopausal estrogen use with cardiovascular disease and its risk factors in older women. Circulation 1993;88:(part 1):2163.
5. Moorjani S, Dupont A, Labrie F et al. Changes in plasma lipoprotein and apolipoprotein composition in relation to oral versus percutaneous administration of estrogen alone or in cyclic association with utrogestan in menopausal women. J Clin Endocrinol Metab 1991;73:373.
6. Krauss RM, Perlman JA, Ray R, Petitti D. Effects of estrogen dose and smoking on lipid and lipoprotein levels in postmenopausal women. Am J Obstet Gynecol 1988;158:1606.
7. Hong MK, Romm PA, Reagan K, Green CE, Rackley CE. Effects of estrogen replacement therapy on serum lipid values and angiographically defined coronary artery disease in postmenopausal women. Am J Cardiol 1992;69:176.
8. Whitehead MI, Fraser D, Schenkel L, Crook D, Stevenson JC. Transdermal administration of oestrogen/progestogen hormone replacement therapy. Lancet 1990;335:310.
9. Cortellaro M, Nencioni T, Boschetti C et al. Cyclic hormonal replacement therapy after the menopause: transdermal versus oral treatment. Eur J Clin Pharmacol 1991;41:555.
10. Lindgren R, Berg G, Hammar M, Larsson-Cohn U, Olsson AG. Plasma lipid and lipoprotein effects of transdermal administration of estradiol and estradiol/norethisterone acetate. Eur J Obstet Gynecol Reprod Biol 1992;47:213.
11. Crook D, Cust MP, Gangar KF et al. Comparison of transdermal and oral estrogen-progestin replacement therapy: effects on serum lipids and lipoproteins. Am J Obstet Gynecol 1992;166:950.
12. Slowinska-Srzednicka J, Zgliczynski S, Chotkowska E et al. Effects of transdermal 17β-oestradiol combined with oral progestogen on lipids and lipoproteins in hypercholesterolaemic postmenopausal women. J Intern Med 1993;234:447.
13. Ziel HK. Estrogen's role in endometrial cancer. Obstet Gynecol 1982;60:509.
14. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995;272:199.
15. Hirvonen E, Mälkönen M, Manninen V. Effects of different progestogens on lipoproteins during postmenopausal replacement therapy. N Engl J Med 1981;304:560.
16. Sporrong T, Hellgren M, Samsioe G, Mattsson L-Å. Metabolic effects of continuous estradiol-progestin therapy in postmenopausal women. Obstet Gynecol 1989;73:754.
17. Hirvonen E, Lipasti A, Mälkönen M et al. Clinical and lipid metabolic effects of unopposed oestrogen and two oestrogen-progestogen regimens in post-menopausal women. Maturitas 1987;9:69.
18. Vaziri SM, Evans JC, Larson MG, Wilson PWF. The impact of female hormone usage on the lipid profile. The Framingham Offspring Study. Arch Intern Med 1993;153:2200.
19. Haarbo J, Hassager C, Jensen SB, Riis BJ, Christiansen C. Serum lipids, lipoproteins, and apolipoproteins during postmenopausal estrogen replacement therapy combined with ether 19-nortestosterone derivates or 17-hydroxyprogesterone derivates. Am J Med 1991;90:584.
20. Tufekci M, Colak Z, Ozan H, Kimya Y, Aydinlar A. Effect of progestogens on estrogen-induced lipoprotein changes. Eur J Obstet Gynecol Reprod Biol 1993;49:169.
21. Patsch JR, Gotto AM. Metabolism of high density lipoproteins. In: Gotto AM (ed). Plasma Lipoproteins. Amsterdam: Elsevier, 1987;221.
22. Schaefer EJ, Ordovas JM. Metabolism of apolipoproteins A-I, A-II and A-IV. In: Segrest JP, Albers JJ (eds). Methods in Enzymology, Plasma Lipoproteins. Vol 129. London: Academic Press, 1986;420.
23. Nikkilä EA, Kuusi T, Taskinen M-R. Role of lipoprotein lipase and hepatic endothelial lipase in the metabolism of high density lipoproteins: a novel concept on cholesterol transport in HDL cycle. In: Carlson LA, Pernow BV (eds). Metabolic Risk Factors in Ischemic Cardiovascular Disease. New York: Raven Press, 1982;205.
24. Tall AR. Plasma cholesteryl ester transfer protein. J Lipid Res 1993;34:1255.
25. Frochlich J, McLeod R, Pritchard H, Fesmire J, McConathy W. Plasma lipoprotein abnormalities in heterozygotes for familial lecithin:cholesterol acyltransferase deficiency. Metabolism 1988;37:3.
26. Cheung MC, Albers JJ. Distribution of high density lipoprotein particles with different apolipoprotein composition: particles with A-I and A-II and particles with A-I but no A-II. J Lipid Res 1982;23:747.
27. Atmeh RF, Shepherd J, Packard CJ. Subpopulations of apolipoprotein A-I in human high-density lipoproteins, their metabolic properties and response to drug therapy. Biochim Biophys Acta 1983;75:175.
28. Cheung MC, Albers JJ. Characterization of lipoprotein particles isolated by immunoaffinity chromatography. J Biol Chem 1984;259:12 201.
29. Parra HJ, Arveiler D, Evans AE et al. A case-control study of lipoprotein particles in two populations at contrasting risk for coronary heart disease. The ECTIM Study. Arterioscler Thromb 1992;12:701.
30. Coste-Burel M, Mainard F, Chivot L, Auget JL, Madec Y. Study of lipoprotein particles LpAI and LpAIAII in patients before coronary bypass surgery. Clin Chem 1990;36:1889.
31. Genest JJ, Bard JM, Fruchart JC, Ordovas JM, Wilson PWF, Schaefer EJ. Plasma apolipoprotein A-I, A-II, B, E and C-III containing particles in men with premature coronary artery disease. Atherosclerosis 1991;90:149.
32. Puchois P, Kandoussi A, Fievet P et al. Apolipoprotein A-I containing lipoproteins in coronary artery disease. Atherosclerosis 1987;68:35.
33. Bass KM, Newschaffer CJ, Klag MJ, Bush TL. Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch Intern Med 1993;153:2209.
34. Taskinen M-R, Puolakka J, Pyörälä T et al. Hormone replacement therapy lowers plasma Lp(a) concentrations: comparison of cyclic transdermal and continuous estrogen-progestin regimens. Arterioscler Thromb Vasc Biol. 1996;16:1215-1221.
35. Ottosen UB, Johansson BG, von Schoultz B. Subfractions of HDL-cholesterol during estrogen replacement therapy: a comparison between progestogens and natural progesterone. Am J Obstet Gynecol 1985;151:746.
36. Havel JR, Eder HA, Bragdon JH. Distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955;34:1345.
37. Groot PHE, Scheek LM, Havekes L, van Noort WL, van't Hooft FM. A one-step separation of human serum high density lipoproteins 2 and 3 by rate-zonal density gradient ultracentrifugation in a swinging bucket rotor. J Lipid Res 1982;23:1342.
38. 107→0) associated with reduced HDL cholesterol and LpA-I:A-II deficiency. Arterioscler Thromb Vasc Biol 1995;15:1294.
39. Nichols AV, Krauss RM, Musliner TA. Nondenaturing polyacrylamide gel electrophoresis. In: Segrest JP, Albers JJ (eds). Methods in Enzymology, Plasma lipoproteins. Vol 128. London: Academic Press, 1986;417.
40. Margolis J, Kenrick KG. Electrophoresis in polyacrylamide concentration gradient. Biochem Biophys Res Commun 1967;27:68.
41. Polyacrylamide Gel Electrophoresis: Laboratory Techniques. Uppsala, Sweden: Pharmacia, Laboratory Separation Division, 1984;16.
42. Huttunen JK, Ehnholm C, Kinnunen PJ, Nikkilä EA. An immunochemical method for selective measurement of two triglyceride lipases in human postheparin plasma. Clin Chim Acta 1975;63:335.
43. Kahri J, Groop P-H, Viberti GC, Elliott T, Taskinen M-R. Regulation of apolipoprotein A-I-containing particles in IDDM. Diabetes 1993;42:1281.
44. Groener JEM, Pelton RW, Kostner GM. Improved estimation of cholesteryl ester transfer/exchange activity in serum or plasma. Clin Chem 1986;32:283.
45. Hannuksela M, Marcel YL, Kesäniemi YA, Savolainen MJ. Reduction in the concentration and activity of cholesteryl ester transfer protein by alcohol. J Lipid Res 1992;33:737.
46. Parra HJ, Mezdour H, Ghalim N, Bard JM, Fruchart JC. Differential electroimmunoassay of human LpA-I lipoprotein particles on ready-to-use plates. Clin Chem 1990;36:1431.
47. Hemmilä I, Dakubu S, Mukkala V-M, Siitari H, Lövgren T. Europium as a label in time-resolved immunofluorometric assays. Ann Biochem 1984;137:335.
48. Mertens R, Liedtke RJ, Batjer JD. Evaluation of a radioimmunoassay for estradiol in unextracted serum. Clin Chem 1983;29:1961.
49. Miller VT, Muesing RA, LaRosa JC, Stoy DB, Phillips EA, Stillman RJ. Effects of conjugated equine estrogen with and without three different progestogens on lipoproteins, high density lipoprotein subfractions, and apolipoprotein A-I. Obstet Gynecol 1991;77:235.
50. Applebaum-Bowden D, McLean P, Steinmetz A et al. Lipoprotein, apolipoprotein, and lipolytic enzyme changes following estrogen administration in postmenopausal women. J Lipid Res 1989;30:1895.
51. Walsh BW, Schiff I, Rosner B, Greenberg L, Ravnikear V, Sacks FM. Effect of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 1991;325:1196.
52. Schaefer EJ, Foster DM, Zech LA, Lindgren FT, Brewer HB, Levy RI. The effects of estrogen administration on plasma lipoprotein metabolism in premenopausal females. J Clin Endocrinol Metab 1983;57:262.
53. Walsh BW, Li H, Sacks FM. Effects of postmenopausal hormone replacement with oral and transdermal estrogen on high density lipoprotein metabolism. J Lipid Res 1994;35:2083.
54. Hazzard WR, Haffner SM, Kushwaha RS, Applebaum-Bowden D, Foster DM. Preliminary report: kinetic studies on the modulation of high density lipoprotein, apolipoprotein, and subfraction metabolism by sex steroids in a postmenopausal woman. Metabolism 1984;33:779.
55. Brinton EA. Oral estrogen replacement therapy in postmenopausal women selectively raises levels and production rates of lipoprotein A-I and lowers hepatic lipase activity without lowering the fractional catabolic rate. Arterioscler Thromb Vasc Biol 1996;16:431.
56. Jensen J, Riis BJ, Strom V, Christiansen C. Continuous oestrogen-progesterogen treatment and serum lipoproteins in postmenopausal women. Br J Obstet Gynecol 1987;94:130.
57. Tikkanen MJ, Nikkilä EA, Kuusi T, Sipinen S. High density lipoprotein-2 and hepatic lipase: reciprocal changes produced by estrogen and norgestrel. J Clin Endocrinol Metab 1982;54:1113.
58. Bamberger M, Lund-Katz S, Phillips MC, Rothblat GH. Mechanism of the hepatic lipase induced accumulation of high-density lipoprotein cholesterol by cells in culture. Biochemistry 1985;24:3693.
59. Colvin PL, Auerbach BJ, Case LD, Harrard WR, Applebaum-Bowden D. A dose-response relationship between sex hormone-induced change in hepatic triglyceride lipase and high-density lipoprotein cholesterol in postmenopausal women. Metabolism 1991;40:1052.
60. Kuusi T, Saarinen P, Nikkilä EA. Evidence for the role of hepatic endothelial lipase in the metabolism of plasma high density lipoprotein 2 in man. Atherosclerosis 1980;36:589.
61. Nikkilä EA, Taskinen M-R, Sane T. Plasma high-density concentration and subfraction distribution in relation to triglyceride metabolism. Am Heart J 1987;113:543.
62. Muesing RA, Miller VT, LaRosa JC, Stoy DB, Phillips EA. Effects of unopposed conjugated equine estrogen on lipoprotein composition and apolipoprotein-E distribution. J Clin Endocrinol Metab 1992;75:1250.
63. Patsch JR, Prasad S, Gotto AM Jr, Patsch W. High density lipoprotein 2. Relationship of the plasma levels of this lipoprotein species to its composition, to the magnitude of postprandial lipemia, and to activities of lipoprotein lipase and hepatic lipase. J Clin Invest 1987;80:341.
64. Patsch JR, Prasad S, Gotto AM Jr, Bengtsson-Olivecrona G. Postprandial lipemia. A key for the conversion of high density lipoprotein 2 to high density lipoprotein 3 by hepatic lipase. J Clin Invest 1984;74:2017.
65. Sacks FM, McPherson R, Walsh BW. Effect of postmenopausal estrogen replacement on plasma Lp(a) lipoprotein concentrations. Arch Intern Med 1994;154:1106.
66. Johansson J, Carlson LA, Landou C, Hamsten A. High density lipoprotein and coronary atherosclerosis. A strong inverse relation with the largest particles is combined to normotriglyceridemic patients. Arterioscler Thromb 1991;11:174.